LeMaitre Vascular Inc. (NASDAQ:LMAT) shares saw strong trading volume on Monday . 107,421 shares were traded during trading, a decline of 11% from the previous session’s volume of 120,130 shares.The stock last traded at $17.39 and had previously closed at $17.33.

Several equities research analysts recently commented on the company. Roth Capital raised their target price on LeMaitre Vascular from $18.00 to $18.50 and gave the stock a “buy” rating in a research note on Tuesday, May 3rd. Canaccord Genuity reaffirmed a “buy” rating and set a $18.00 target price (up previously from $6.00) on shares of LeMaitre Vascular in a research note on Tuesday, May 3rd. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Thursday, May 5th. Brean Capital reiterated a “buy” rating on shares of LeMaitre Vascular in a report on Tuesday, May 3rd. Finally, Barrington Research increased their price target on LeMaitre Vascular from $18.50 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, July 28th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $18.72.

The firm’s 50-day moving average price is $15.76 and its 200-day moving average price is $15.02. The company has a market cap of $320.17 million and a P/E ratio of 34.82.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Wednesday, July 27th. The company reported $0.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.03. The company had revenue of $22.40 million for the quarter, compared to the consensus estimate of $21.59 million. The firm’s revenue was up 12.6% compared to the same quarter last year. Equities research analysts forecast that LeMaitre Vascular Inc. will post $0.55 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Monday, August 22nd will be paid a dividend of $0.045 per share. This represents a $0.18 annualized dividend and a dividend yield of 1.04%. The ex-dividend date of this dividend is Thursday, August 18th.

In other news, Chairman George W. Lemaitre sold 4,540 shares of LeMaitre Vascular stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $17.65, for a total transaction of $80,131.00. Following the completion of the sale, the chairman now owns 3,516,387 shares of the company’s stock, valued at $62,064,230.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Trent G. Kamke sold 2,510 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $15.00, for a total transaction of $37,650.00. Following the sale, the insider now directly owns 15,573 shares of the company’s stock, valued at approximately $233,595. The disclosure for this sale can be found here.

An institutional investor recently raised its position in LeMaitre Vascular stock. Cornerstone Capital Management Holdings LLC. raised its stake in shares of LeMaitre Vascular Inc. (NASDAQ:LMAT) by 337.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,289 shares of the company’s stock after buying an additional 49,589 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.35% of LeMaitre Vascular worth $1,109,000 at the end of the most recent reporting period.

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.